about
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatristsMozart's music in children with drug-refractory epileptic encephalopathies.Quetiapine monotherapy in adolescents with bipolar disorder comorbid with conduct disorderHealth-related quality of life in pediatric liver transplanted patients compared with a chronic liver disease group.Epidemiological study on behavioural and emotional problems in developmental age: prevalence in a sample of Italian children, based on parent and teacher reports.Massive asymptomatic creatine kinase elevation in youth during antipsychotic drug treatment: case reports and critical review of the literature.Psychiatric and neuropsychological issues in Marfan syndrome: A critical review of the literature.Psychiatric evaluation of youths with Disruptive Behavior Disorders and psychopathic traits: A critical review of assessment measures.Ketogenic diet and childhood neurological disorders other than epilepsy: an overview.Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch.Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients: A 2-Year Naturalistic Comparison.Combined pharmacotherapy-multimodal psychotherapy in children with Disruptive Behavior Disorders.Paranoid Thoughts in Adolescents with Social Anxiety Disorder.Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings.Child behavior checklist dysregulation profile in children with disruptive behavior disorders: A longitudinal study.Efficacy and Safety of Risperidone and Quetiapine in Adolescents With Bipolar II Disorder Comorbid With Conduct Disorder.Conduct disorders and psychopathy in children and adolescents: aetiology, clinical presentation and treatment strategies of callous-unemotional traitsChild behaviour checklist emotional dysregulation profiles in youth with disruptive behaviour disorders: clinical correlates and treatment implications.The Rorschach Test Evaluation in Chronic Childhood Migraine: A Preliminary Multicenter Case–Control Study.Different Immune Signature in Youths Experiencing Antipsychotic-Induced Weight Gain Compared to Untreated Obese Patients.Maternal Stress and Coping Strategies in Developmental Dyslexia: An Italian Multicenter Study.Non suicidal self-injury in referred adolescents with mood disorders and its association with cyclothymic-hypersensitive temperament.Putative mechanisms of action and clinical use of lithium in children and adolescents: a critical review.Is emotional dysregulation a risk indicator for auto-aggression behaviors in adolescents with oppositional defiant disorder?Which dimension of parenting predicts the change of callous unemotional traits in children with disruptive behavior disorder?Ketogenic diet prevents neuronal firing increase within the substantia nigra during pentylenetetrazole-induced seizure in rats.Callous unemotional traits in children with disruptive behavior disorder: Predictors of developmental trajectories and adolescent outcomes.Psychotic-like experiences in help-seeking adolescents: Dimensional exploration and association with different forms of bullying victimization - A developmental social psychiatry perspective.Mozart's music in children with drug-refractory epileptic encephalopathies: Comparison of two protocols.Emotional reactivity in referred youth with disruptive behavior disorders: the role of the callous-unemotional traits.Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths.High-functioning autism spectrum disorder associated with CHARGE syndrome: a case report.Psychiatric Manifestation of EAST Syndrome: Case Report and a Critical Assessment of Psychiatric Issues.On the Possible Relationship Between Anti-Streptolysin-O Titer and Neuropsychiatric Disorders Other than PANS.Second generation antipsychotics in adolescent anorexia nervosa: a new hypothesis of eligibility criteria.Antipsychotic-Induced Dyslipidemia Treated with Omega 3 Fatty Acid Supplement in an 11-Year-Old Psychotic Child: A 1-Year Follow-upLithium treatment in bipolar adolescents: a follow-up naturalistic studyTrajectories of callous-unemotional traits from childhood to adolescence in referred youth with a disruptive behavior disorder who received intensive multimodal therapy in childhoodPhantom Phone Signals in youths: Prevalence, correlates and relation to psychopathologyUse of quetiapine in children and adolescents
P50
Q26747123-659FA428-3B33-4325-A8BE-398989714073Q30375914-FF548218-F89D-4475-8F48-66E491FAD4BAQ37245094-CA17164B-72B7-416E-9620-0542B0D7FD6EQ37356212-421B369D-442A-4D4A-A7D9-9D8D25429C3CQ37679137-C3F1F08E-30C6-47B4-81EC-E19AAA8648ECQ38267154-5C497DC5-8588-420A-A33A-1CAB23BE3D7FQ38622823-72FE268B-D037-4099-AA59-58FC02FF506AQ38966231-12711475-F6F9-4A9C-B960-BACA47FD6836Q39007510-100E9785-8203-412B-A902-F5033E61D357Q39162868-A6153B50-E148-4882-99B9-2A9DAC42DAADQ39250552-E65A2E32-D723-45F3-B9FE-594F7960FEA0Q39845185-1458795E-CD90-42B5-B229-3B27D6B0E463Q40219891-6873F790-8C05-4E9C-AAC0-8457F56746DFQ40267262-E51A9027-60DC-40BF-B313-7733AF1F9CBAQ40645880-E8F4A4F9-BD73-4FBC-B7EC-AE173F519BABQ40677590-E2ECB8E8-1DB6-4C31-8B9D-C3361175D234Q41696244-56AC8CBA-F881-4346-9391-0344FFCDFC3CQ41722160-E38F48A1-DB65-449C-A380-23E73C878EC8Q47176801-F24FFEB0-2A73-4B69-8AC2-78183FFADA72Q47217222-1EA3BE04-F459-402D-B64F-ADD392DED86DQ47274855-A965CB4E-9E5F-4377-BDED-BC3CE8AE5094Q47274913-9675FDD6-E733-4F17-B23F-96C9F0AA76CBQ47284608-7940D77C-2FDB-460B-AD16-0D2DCC70A3B9Q47382372-E52E96EF-5C0F-42DA-A570-FB86BA053045Q47410199-08E2FD1A-1898-4B4E-AFC0-4F82E8675895Q47412024-A1E0F090-79BA-4769-B1C0-C1B02DCD3FD0Q47593783-D007B2F8-D755-4884-8060-1D1F2DB988A7Q47603095-A99B8E13-DA76-44C9-8361-D4A32846CEC7Q47659246-D88E5C38-DF75-4271-BFBA-AD636975AA10Q47833624-B208836D-D4E1-4B2D-91F9-7F7731BA36F4Q50050580-30E941F3-BD10-4823-B09F-24D093A355BFQ50309490-EC10FD48-E95A-46A9-840D-12166FEC0670Q50317101-6DB6905C-0959-4DB4-A055-65A021CA946DQ50581931-828BC93A-131F-494E-BCD9-FF555E48BAFBQ50643785-1E4713D1-ADB4-424B-8DCE-63200987DA42Q57885319-BFE714A9-2DA3-4B65-B1CB-222D32F1F50DQ58698888-C4E78CBF-6363-4305-BA35-9FB1ED6C059BQ58763075-EEFC3F8F-7DCB-4386-83B6-84800AC60CBAQ60921050-6E8848A3-7BA3-43EE-8479-1C7E41D30479Q86747533-AA5DE9D4-C4A6-4E72-BB11-696FBD4B0437
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Simone Pisano
@ast
Simone Pisano
@en
Simone Pisano
@es
Simone Pisano
@nl
type
label
Simone Pisano
@ast
Simone Pisano
@en
Simone Pisano
@es
Simone Pisano
@nl
prefLabel
Simone Pisano
@ast
Simone Pisano
@en
Simone Pisano
@es
Simone Pisano
@nl
P106
P1153
54397583800
P31
P496
0000-0001-5704-4483